Latest On Seneca Biopharma, Inc (CUR):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2020-09-26 12:29 EST | Financials | Company financials have been released. | Neutral |  |
| 2020-09-17 04:37 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-15 04:28 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-14 08:31 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-31 00:42 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-23 16:45 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-09 08:27 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 08:30 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-27 04:31 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-06 04:33 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-03 08:36 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-07 12:32 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-07 00:42 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-28 23:33 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-28 03:34 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-21 23:27 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-14 23:26 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-06 23:29 EST | Financials | Company financials have been released. | Neutral | |
| 2020-01-29 23:29 EST | Financials | Company financials have been released. | Neutral | |
| 2020-01-27 23:27 EST | Financials | Company financials have been released. | Neutral | |
| 2020-01-15 23:28 EST | Financials | Company financials have been released. | Neutral | |
| 2019-12-21 23:18 EST | Financials | Company financials have been released. | Neutral | |
| 2019-12-16 23:27 EST | Financials | Company financials have been released. | Neutral | |
| 2019-12-02 23:17 EST | Financials | Company financials have been released. | Neutral | |
| 2019-12-02 03:18 EST | Stock Split | A stock split has occured on Jul 18, 2019 with a split factor of 20/1. | Neutral | |
| 2019-11-27 23:27 EST | Financials | Company financials have been released. | Neutral | |
| 2019-11-26 23:27 EST | Financials | Company financials have been released. | Neutral | |
| 2019-11-22 23:25 EST | Financials | Company financials have been released. | Neutral | |
| 2019-11-21 23:19 EST | Stock Split | A stock split has occured on Jul 18, 2019 with a split factor of 20/1. | Neutral | |
| 2019-11-15 23:26 EST | Financials | Company financials have been released. | Neutral | |
| 2019-11-12 23:18 EST | Stock Split | A stock split has occured on Jul 18, 2019 with a split factor of 20/1. | Neutral | |
| 2019-11-06 23:25 EST | Financials | Company financials have been released. | Neutral | |
| 2019-07-01 01:05 EST | Insider Trade | SANDFORD D SMITH has directly acquired 166,667 shares and currently holds 219,916 shares. | Buy | |
| 2019-06-30 01:05 EST | Financials | Company financials have been released. | Neutral | |
| 2019-03-31 01:05 EST | Financials | Company financials have been released. | Neutral | |
| 2018-12-31 00:05 EST | Financials | Company financials have been released. | Neutral | |
| 2018-09-30 01:05 EST | Financials | Company financials have been released. | Neutral | |
| 2018-07-02 01:05 EST | Insider Trade | SANDFORD D SMITH has directly acquired 45,046 shares and currently holds 50,899 shares. | Buy | |
| 2018-06-30 01:05 EST | Financials | Company financials have been released. | Neutral | |
| 2017-08-08 01:05 EST | Earnings | Earnings have been released on August 8, 2017, with -$7.20 earnings per share. | Buy | |
| 2017-03-23 01:05 EST | Earnings | Earnings have been released on March 23, 2017, with -$8.60 earnings per share. | Buy | |
| 2017-01-23 00:05 EST | Earnings | Earnings have been released on January 23, 2017, with -$14.00 earnings per share. | Sell | |
| 2016-11-08 00:05 EST | Earnings | Earnings have been released on November 8, 2016, with -$11.82 earnings per share. | Sell | |
About Seneca Biopharma, Inc (CUR):
Seneca Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its lead product candidate is NSI-189, a chemical entity, which has been completed Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical study for the treatment-refractory depression, Angelman Syndrome, Alzheimer's disease, ischemic stroke, diabetic neuropathy, irradiation-induced cognitive deficit, and long-term potentiation enhancement. The company also develops NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease; Phase II clinical trial for the treatment of chronic ischemic stroke; and Phase I clinical trials for the treatment of chronic spinal cord injury, as well as is in preclinical study for the traumatic brain injury. In addition, it develops NSI-532, which is in preclinical study for treatment of Alzheimer's disease; and NSI-777 that is in preclinical study for treatment of human demyelinating diseases. The company was formerly known as Neuralstem, Inc. and changed its name to Seneca Biopharma, Inc. in October 2019. Seneca Biopharma, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
General
- Name Seneca Biopharma, Inc
- Symbol CUR
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorOther
- IndustryOther
- Full Time Employees 5
- Last Split Date
- Fiscal Year EndDecember
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLwww.neuralstem.com
View More
Highlights
- Market Capitalization 4.01 million
- EBITDA -8336793
- Analyst Target Price $26
- Book Value Per Share $2.50
View More
Share Statistics
- % Held by Insiders <1%
View More
Technicals
- 52 Week High $2.12
- 52 Week Low $0.19
View More
Dividends
- Dividend Date
- ExDividend Date
View More
Seneca Biopharma, Inc (CUR) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Seneca Biopharma, Inc (CUR) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2018-12-31 | 2019-03-22 | $2500 | -$3.42 | ||
| 2018-06-30 | 2018-08-15 | $252500 | -$2.41 | ||
| 2017-12-31 | 2018-03-23 | $252000 | -$2.84 | ||
| 2017-09-30 | 2017-11-13 | $2500 | -$3.58 | ||
| 2017-06-30 | 2017-08-08 | $2500 | -$7.20 | -$14.60 | 50.68% |
| 2016-12-31 | 2017-03-23 | $8000 | -$14.00 | -$10.40 | -34.62% |
| 2016-09-30 | 2016-11-08 | $2500 | -$11.82 | -$0.46 | -2468.96% |
| 2016-06-30 | 2016-08-12 | $2500 | -$9.46 | ||
| 2015-12-31 | 2016-03-15 | $2500 | -$18.67 | ||
| 2015-09-30 | 2015-11-09 | $2500 | -$16.01 | ||
| 2015-06-30 | 2015-08-10 | $2500 | -$15.60 | ||
| 2014-12-31 | 2015-03-16 | $5000 | -$14.65 | ||
| 2014-09-30 | 2014-11-07 | $5000 | -$13.26 | ||
| 2014-06-30 | 2014-08-08 | $5000 | -$20.13 | ||
| 2013-12-31 | 2014-03-10 | $2500 | -$17.95 | ||
| 2013-09-30 | 2013-11-13 | $2500 | -$23.82 | ||
| 2013-06-30 | 2013-08-09 | $2500 | -$23.27 | ||
| 2012-12-31 | 2013-03-15 | $2500 | -$13.59 | ||
| 2012-09-30 | 2012-11-09 | $171000 | -$11.48 | ||
| 2012-06-30 | 2012-08-10 | $78000 | -$11.42 | ||
| 2011-12-31 | 2012-03-30 | $288000 | -$12.40 | ||
| 2011-09-30 | 2011-11-10 | $103000 | -$17.22 | ||
| 2011-06-30 | 2011-08-10 | $N/A | -$19.57 | ||
| 2010-12-31 | 2011-03-16 | $733000 | -$16.91 | ||
| 2010-09-30 | 2010-11-16 | $N/A | -$22.14 | ||
| 2010-06-30 | 2010-08-17 | $N/A | -$30.33 | ||
| 2010-03-31 | 2010-05-18 | $N/A | -$20.80 | ||
| 2009-09-30 | 2009-11-17 | $N/A | -$38.34 | ||
| 2009-03-31 | 2009-05-18 | $N/A | -$27.69 | ||
| 2008-06-30 | 2008-08-15 | $N/A | -$25.70 | ||
| 2007-12-31 | 2008-02-27 | $260000 | -$18.62 | ||
| 2007-09-30 | 2007-11-14 | $46000 | -$12.59 | ||
| 2007-06-30 | 2007-06-30 | $78000 | -$16.11 | ||
| 2007-03-31 | 2007-03-31 | $182000 | -$9.28 | ||
| 2006-12-31 | 2006-12-31 | $57000 | -$13.60 |
Seneca Biopharma, Inc (CUR) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 | Jun 30 2019 | Mar 31 2019 |
|---|---|---|---|---|---|
| Research Development | 696889 | 767048 | 825486 | 954453 | 1.29 million |
| Income Before Tax | -7.58 million | -2.04 million | -1.76 million | -1.44 million | -3.11 million |
| Selling General Administrative | 1.3 million | 1.37 million | 1.3 million | 971822 | 944602 |
| Gross Profit | N/A | N/A | 2500 | 7894 | 2500 |
| Ebit | -7.57 million | -2.03 million | -2.12 million | -1.92 million | -2.23 million |
| Operating Income | -1.99 million | -2.13 million | -2.12 million | -1.92 million | -2.23 million |
| Income Tax Expense | N/A | N/A | N/A | N/A | N/A |
| Total Revenue | N/A | N/A | 2500 | 7894 | 2500 |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A |
| Total Other Income Expense Net | N/A | N/A | 361041 | 481460 | -880427 |
| Net Income From Continuing Operations | -7.58 million | -2.04 million | -1.76 million | -1.44 million | -3.11 million |
| Net Income Applicable to Common Shares | -7.58 million | -2.04 million | -1.76 million | -1.44 million | -3.11 million |
Cash Flow:
| Date | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 | Jun 30 2019 | Mar 31 2019 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | N/A | N/A | N/A |
| Change to Liabilities | 102690 | -220032 | 132201 | -35847 | 244319 |
| Total Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Net Borrowings | -138735 | -136832 | 369128 | -78850 | -117019 |
| Total Cash Flow from Financial Activities | 6.59 million | -136727 | 6.92 million | -78850 | -117019 |
| Change to Operating Activities | N/A | N/A | -747633 | 31306 | 429591 |
| Change in Cash | 4.92 million | -2.19 million | 5.02 million | -1.72 million | -1.78 million |
| Total Cash from Operating Activities | -1.68 million | -2.05 million | -1.9 million | -1.64 million | -1.67 million |
| Depreciation | 29078 | 30124 | 36584 | 37330 | 39821 |
| Other Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Inventory | N/A | N/A | N/A | N/A | N/A |
| Change to Account Receivables | N/A | N/A | 108751 | 67877 | 56275 |
| Other Cash Flow from Financing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Net Income | 51267 | 37103 | 335991 | -307348 | 678081 |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A |
Balance Sheet:
| Date | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 | Jun 30 2019 | Mar 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | 1.38 million | 1.46 million | 1.9 million | 1.56 million | 2.13 million |
| Total Stockholder Equity | 9.98 million | 5.13 million | 7.04 million | 1.96 million | 3.26 million |
| Other Current Liabilities | 262845 | 264665 | N/A | 37 | 78830 |
| Total Assets | 11.36 million | 6.58 million | 8.94 million | 3.52 million | 5.41 million |
| Common Stock | 94280 | 38665 | 28183 | 10018 | 182051 |
| Other Current Assets | 1.28 million | 510900 | N/A | 970041 | 295406 |
| Retained Earnings | -229.55 million | -221.98 million | -219.94 million | -218.17 million | -216.74 million |
| Other Liabilities | N/A | N/A | 166938 | 487723 | 923849 |
| Other Assets | N/A | N/A | 32841 | 23001 | 19454 |
| Cash | 10.03 million | 5.11 million | 7.3 million | 2.28 million | 4.01 million |
| Total Current Liabilities | 1.19 million | 1.22 million | 1.58 million | 1.07 million | 1.21 million |
| Other Stockholder Equity | -7148 | -6186 | -7670 | -3169 | -2156 |
| Property, Plant & Equipment | 31130 | 41036 | 256243 | 77341 | 109568 |
| Total Current Assets | 10.46 million | 5.65 million | 7.97 million | 2.71 million | 4.54 million |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | 9.98 million | 4.46 million | 6.35 million | 1.24 million | 2.52 million |
| Short Term Investments | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A |
| Inventory | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | 1.06 million | 960092 | 1.18 million | 1.05 million | 1.08 million |
Seneca Biopharma, Inc (CUR) Chart:
Seneca Biopharma, Inc (CUR) News:
Below you will find a list of latest news for Seneca Biopharma, Inc (CUR) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Seneca Biopharma, Inc (CUR) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Seneca Biopharma, Inc (CUR) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2019-06-27 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1357459/000000000019010410/0000000000-19-010410-index.htm |
| 2018-11-05 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1357459/000091957418006983/0000919574-18-006983-index.htm |
| 2019-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1357459/000091957419001735/0000919574-19-001735-index.htm |
| 2018-02-09 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1357459/000110465918007912/0001104659-18-007912-index.htm |
| 2017-11-08 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1357459/000117184317006717/0001171843-17-006717-index.htm |
| 2017-11-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1357459/000117184317006832/0001171843-17-006832-index.htm |
| 2017-11-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1357459/000117184317007063/0001171843-17-007063-index.htm |
| 2017-12-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1357459/000117184317007470/0001171843-17-007470-index.htm |
| 2017-12-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1357459/000117184317007761/0001171843-17-007761-index.htm |
| 2018-01-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1357459/000117184318000260/0001171843-18-000260-index.htm |
| 2018-01-24 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1357459/000117184318000605/0001171843-18-000605-index.htm |
| 2018-03-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1357459/000117184318002047/0001171843-18-002047-index.htm |
| 2018-04-02 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1357459/000117184318002404/0001171843-18-002404-index.htm |
| 2018-04-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1357459/000117184318002467/0001171843-18-002467-index.htm |
| 2018-04-25 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1357459/000117184318003047/0001171843-18-003047-index.htm |
| 2018-04-25 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1357459/000117184318003048/0001171843-18-003048-index.htm |
| 2018-05-15 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1357459/000117184318003929/0001171843-18-003929-index.htm |
| 2018-05-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1357459/000117184318003930/0001171843-18-003930-index.htm |
| 2018-06-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1357459/000117184318004525/0001171843-18-004525-index.htm |
| 2018-06-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1357459/000117184318004653/0001171843-18-004653-index.htm |
| 2018-06-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1357459/000117184318004654/0001171843-18-004654-index.htm |
| 2018-07-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1357459/000117184318005063/0001171843-18-005063-index.htm |
| 2018-07-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1357459/000117184318005064/0001171843-18-005064-index.htm |
| 2018-07-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1357459/000117184318005065/0001171843-18-005065-index.htm |
| 2018-07-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1357459/000117184318005067/0001171843-18-005067-index.htm |
| 2018-07-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1357459/000117184318005068/0001171843-18-005068-index.htm |
| 2018-07-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1357459/000117184318005071/0001171843-18-005071-index.htm |
| 2018-08-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1357459/000117184318005954/0001171843-18-005954-index.htm |
| 2018-08-13 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1357459/000117184318006008/0001171843-18-006008-index.htm |
| 2018-08-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1357459/000117184318006114/0001171843-18-006114-index.htm |
| 2018-10-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1357459/000117184318007287/0001171843-18-007287-index.htm |
| 2018-10-29 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1357459/000117184318007288/0001171843-18-007288-index.htm |
| 2018-11-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1357459/000117184318007951/0001171843-18-007951-index.htm |
| 2018-11-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1357459/000117184318008002/0001171843-18-008002-index.htm |
| 2018-11-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1357459/000117184318008250/0001171843-18-008250-index.htm |
| 2018-12-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1357459/000117184318008473/0001171843-18-008473-index.htm |
| 2019-02-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1357459/000117184319000835/0001171843-19-000835-index.htm |
| 2019-03-22 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1357459/000117184319001917/0001171843-19-001917-index.htm |
| 2019-03-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1357459/000117184319001924/0001171843-19-001924-index.htm |
| 2019-04-19 | PRE 14A | Other preliminary proxy statements | https://www.sec.gov/Archives/edgar/data/1357459/000117184319002519/0001171843-19-002519-index.htm |
| 2019-04-29 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1357459/000117184319002717/0001171843-19-002717-index.htm |
| 2019-04-29 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1357459/000117184319002718/0001171843-19-002718-index.htm |
| 2019-05-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1357459/000117184319002971/0001171843-19-002971-index.htm |
| 2019-05-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1357459/000117184319003354/0001171843-19-003354-index.htm |
| 2019-05-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1357459/000117184319003356/0001171843-19-003356-index.htm |
| 2019-06-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1357459/000117184319003762/0001171843-19-003762-index.htm |
| 2019-06-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1357459/000117184319004037/0001171843-19-004037-index.htm |
| 2019-06-21 | S-1 | General form for registration of securities under the Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1357459/000117184319004112/0001171843-19-004112-index.htm |
| 2019-06-27 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1357459/000117184319004224/0001171843-19-004224-index.htm |
| 2019-07-03 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1357459/000117184319004414/0001171843-19-004414-index.htm |
| 2019-07-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1357459/000117184319004415/0001171843-19-004415-index.htm |
| 2019-07-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1357459/000117184319004416/0001171843-19-004416-index.htm |
| 2019-07-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1357459/000117184319004417/0001171843-19-004417-index.htm |
| 2019-07-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1357459/000117184319004418/0001171843-19-004418-index.htm |
| 2019-07-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1357459/000117184319004419/0001171843-19-004419-index.htm |
| 2019-07-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1357459/000117184319004639/0001171843-19-004639-index.htm |
| 2019-07-22 | S-1/A | General form for registration of securities under the Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1357459/000117184319004682/0001171843-19-004682-index.htm |
| 2019-07-22 | FWP | Filing under Securities Act Rules 163/433 of free writing prospectuses | https://www.sec.gov/Archives/edgar/data/1357459/000117184319004683/0001171843-19-004683-index.htm |
| 2019-07-24 | S-1/A | General form for registration of securities under the Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1357459/000117184319004802/0001171843-19-004802-index.htm |
| 2019-07-25 | S-1/A | General form for registration of securities under the Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1357459/000117184319004822/0001171843-19-004822-index.htm |
| 2019-07-25 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1357459/000117184319004824/0001171843-19-004824-index.htm |
| 2019-07-29 | 424B4 | Prospectus [Rule 424(b)(4)] | https://www.sec.gov/Archives/edgar/data/1357459/000117184319004942/0001171843-19-004942-index.htm |
| 2019-08-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1357459/000117184319005227/0001171843-19-005227-index.htm |
| 2019-08-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1357459/000117184319005480/0001171843-19-005480-index.htm |
| 2019-08-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1357459/000117184319005491/0001171843-19-005491-index.htm |
| 2019-09-17 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1357459/000117184319005971/0001171843-19-005971-index.htm |
| 2019-09-24 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1357459/000117184319006101/0001171843-19-006101-index.htm |
| 2019-10-11 | 4/A | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1357459/000117184319006480/0001171843-19-006480-index.htm |
| 2019-10-11 | 4/A | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1357459/000117184319006481/0001171843-19-006481-index.htm |
| 2019-10-11 | 4/A | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1357459/000117184319006482/0001171843-19-006482-index.htm |
| 2019-10-11 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1357459/000117184319006483/0001171843-19-006483-index.htm |
| 2019-10-11 | 3/A | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1357459/000117184319006484/0001171843-19-006484-index.htm |
| 2019-10-11 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1357459/000117184319006485/0001171843-19-006485-index.htm |
| 2019-10-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1357459/000117184319006925/0001171843-19-006925-index.htm |
| 2019-11-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1357459/000117184319007138/0001171843-19-007138-index.htm |
| 2019-11-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1357459/000117184319007531/0001171843-19-007531-index.htm |
| 2019-11-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1357459/000117184319007574/0001171843-19-007574-index.htm |
| 2019-08-09 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1357459/000121390019015064/0001213900-19-015064-index.htm |
| 2018-02-02 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1357459/000139382518000020/0001393825-18-000020-index.htm |
| 2018-10-26 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1357459/000153561018000102/0001535610-18-000102-index.htm |
| 2019-01-07 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1357459/000153561019000043/0001535610-19-000043-index.htm |
| 2019-07-25 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1357459/999999999519001693/9999999995-19-001693-index.htm |
Seneca Biopharma, Inc (CUR) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Seneca Biopharma, Inc (CUR). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: < 1%Institutional Ownership: < 1%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2019-07-01 | SANDFORD D SMITH | Director | Buy | 166,667.00 | 219,916.00 | https://www.sec.gov/Archives/edgar/data/1357459/000117184319004419/0001171843-19-004419-index.htm | ||
| 2018-07-02 | SANDFORD D SMITH | Director | Buy | 45,046.00 | 50,899.00 | https://www.sec.gov/Archives/edgar/data/1357459/000117184318005063/0001171843-18-005063-index.htm |